About L-dopachrome tautomerase
L-dopachrome tautomerase (DCT) is a protein
from Homo sapiens identified by UniProt accession
P40126, 519 residues long.
MolForge cross-references it against 0 known binders and
186 disease associations.
Target properties
| Protein name | L-dopachrome tautomerase |
| UniProt accession | P40126 |
| Gene | DCT |
| Organism | Homo sapiens |
| Length | 519 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (186)
Diseases linked to this target (Open Targets).
- oculocutaneous albinism type 8 · score 0.67
- albinism · score 0.36
- skin pigmentation · score 0.35
- Familial adenomatous polyposis · score 0.34
- classic familial adenomatous polyposis · score 0.34
- hair color · score 0.34
- age related macular degeneration 7 · score 0.33
- hair colour measurement · score 0.33
- kidney disease · score 0.32
- suntan · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P40126-F1 | alphafold | PREDICTED | 89.10 | — |
Amino-acid sequence (519 residues)
MSPLWWGFLL SCLGCKILPG AQGQFPRVCM TVDSLVNKEC CPRLGAESAN VCGSQQGRGQ CTEVRADTRP WSGPYILRNQ DDRELWPRKF FHRTCKCTGN FAGYNCGDCK FGWTGPNCER KKPPVIRQNI HSLSPQEREQ FLGALDLAKK RVHPDYVITT QHWLGLLGPN GTQPQFANCS VYDFFVWLHY YSVRDTLLGP GRPYRAIDFS HQGPAFVTWH RYHLLCLERD LQRLIGNESF ALPYWNFATG RNECDVCTDQ LFGAARPDDP TLISRNSRFS SWETVCDSLD DYNHLVTLCN GTYEGLLRRN QMGRNSMKLP TLKDIRDCLS LQKFDNPPFF QNSTFSFRNA LEGFDKADGT LDSQVMSLHN LVHSFLNGTN ALPHSAANDP IFVVLHSFTD AIFDEWMKRF NPPADAWPQE LAPIGHNRMY NMVPFFPPVT NEELFLTSDQ LGYSYAIDLP VSVEETPGWP TTLLVVMGTL VALVGLFVLL AFLQYRRLRK GYTPLMETHL SSKRYTEEA
Explore L-dopachrome tautomerase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets